Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...

Teva is looking to evolve its business through ... NTEs would then gain five years of market exclusivity. One clear commercial hurdle will be cost: if the company puts too high a price on its ...

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). The product is indicated for the ...

PARSIPPANY, N.J. and REYKJAVÍK, Iceland, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and ...

Teva's Senior Vice President emphasized the cost-saving potential of biosimilars, while Alvotech's Chief Commercial Officer highlighted the partnership's dedication to expanding the high-quality ...

while Teva's discontinuation follows similar commercial considerations. Benazepril hydrochloride capsule: Aurobindo Pharma USA has discontinued the 10-, 20- and 40-milligram presentations of ...

"I don't think having Teva part of that and having Austedo, a rare disease (treatment), part of that is necessarily the intent of the IRA," he said. Speaking at the news conference on Monday ...

Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, ...